ICT 04
Alternative Names: ICT-04Latest Information Update: 28 Jan 2021
At a glance
- Originator ImCheck Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 13 Jan 2021 Early research in Haematological malignancies in France (Parenteral) (ImCheck Therapeutics pipeline, January 2021)
- 13 Jan 2021 Early research in Solid tumours in France (Parenteral) (ImCheck Therapeutics pipeline, January 2021)